source
- Ionis secures FDA approval for Zanvastro, first disease-modifying therapy for rare Alexander diseaseIonis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Zanvastro, marking the first disease-modifying treatment for Alexander disease, a rare and often fatal neurol…
- GSK licenses Hutchmed's KRAS-EGFR antibody-drug conjugate for $110 million upfrontGSK announced it will pay $110 million upfront to obtain a license for a KRAS-EGFR antibody-drug conjugate developed by Chinese biopharma Hutchmed. The agreement also includes potential milestone p…